SHANGHAI – After being burned by several failed partnering attempts, China’s top CRO WuXi PharmaTech Inc. has formed a joint venture with U.S.-based contract research organization PRA to expand clinical trial services in the mainland, Hong Kong and Macau.
WuXi and PRA plan to combine their China clinical operations to form an independent CRO providing services like clinical trial...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?